Carvykti access in UAE: travel-for-treatment coordination for BCMA CAR-T

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team. Carvykti is FDA-approved for relapsed or refractory multiple myeloma (second-line eligible since April 2024). Carvykti is not stocked in the UAE and cannot be administered outside a manufacturer-certified treatment center. UAE patients access it through travel-for-treatment, not through a conventional shipment of medicine into the country.

Quick orientation for UAE patients

Carvykti, the brand name for ciltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen (BCMA) directed autologous CAR T-cell therapy co-developed by Janssen Biotech (Johnson and Johnson) and Legend Biotech. The U.S. Food and Drug Administration first approved Carvykti on 28 February 2022 for relapsed or refractory multiple myeloma after four or more prior lines, and expanded the indication on 5 April 2024 to patients who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent and who are refractory to lenalidomide. Carvykti is unlike a conventional named-patient medicine. Each dose is manufactured from the individual patient's own T-cells, takes 30 to 45 days from apheresis to release, must be stored at or below minus 150 degrees Celsius in liquid nitrogen vapor, and can only be infused at a manufacturer-certified REMS-equivalent treatment center under CRS and ICANS monitoring infrastructure. There is no Carvykti administration capacity in the UAE today. The realistic path for a UAE-resident patient is travel to a qualified Carvykti center in the US, EU, UK, or Japan. Reserve Meds coordinates the patient-side travel, the apheresis-manufacture-return calendar, and the family logistics around a 6 to 10 week treatment arc. Reserved for you.

Why UAE patients reach for Carvykti via cross-border coordination

Multiple myeloma patients in the UAE who have progressed on standard lines (proteasome inhibitor, immunomodulatory agent, anti-CD38 monoclonal antibody) and whose treating hematologist has identified CAR-T as the next step face a different access problem than the typical named-patient case. Carvykti the molecule is not what is unavailable; the operational chain required to deliver it is what is unavailable locally. Four constraints drive the cross-border path: there is no local REMS-equivalent certified treatment center capable of safely administering BCMA CAR-T with the required cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome monitoring infrastructure, there is no local Janssen-Legend qualified apheresis collection site, there is no local manufacturing slot allocation, and the cost envelope (including hospitalization and complication management) sits well outside any UAE public-payer coverage construct.

UAE oncology infrastructure has been growing; Sheikh Khalifa Medical City, Cleveland Clinic Abu Dhabi, Tawam Hospital, and American Hospital Dubai handle complex hematology cases. But none holds Carvykti REMS certification or a Janssen-Legend manufacturing slot allocation as of this review. The MOHAP and EDE unregistered-medicine framework is not the mechanism that bridges this gap. The bridge is travel. A patient effectively cannot receive Carvykti without traveling to a country where Janssen-Legend has both a qualified apheresis collection site and a REMS-certified infusion center, or without a manufacturer-supported cross-border arrangement that is exceptional rather than routine.

The MOHAP and EDE framework versus the Carvykti reality

The MOHAP and EDE unregistered-medicine import permit (administered through the EDE portal at ede.gov.ae from 29 December 2025 under Federal Decree-Law No. 38 of 2024) is the federal pathway for medicines that can be imported and dispensed locally. Carvykti is not in this category. The product is not a shelf-stable molecule that ships into a hospital pharmacy. It is a patient-specific batch tied to that patient's apheresis collection, stored in liquid nitrogen vapor at temperatures at or below minus 150 degrees Celsius, with a narrow post-thaw window that mandates infusion at the manufacturing-aligned center.

The practical document set for a UAE patient pursuing Carvykti therefore looks different from a routine NPP file. The treating UAE hematologist's clinical justification letter establishes the multiple myeloma diagnosis (relapsed or refractory after the relevant prior lines), summarises prior-line history (proteasome inhibitor, immunomodulatory agent, anti-CD38 monoclonal antibody, and the lenalidomide-refractory status if pursuing under the second-line label), the patient's performance status, organ function, and absence of contraindications, and the rationale for BCMA CAR-T (Carvykti or Abecma, the other FDA-approved BCMA CAR-T). The destination Carvykti REMS-certified treatment center then conducts its own intake under its standard process, confirms apheresis eligibility, schedules a manufacturing slot, and admits the patient. There is no UAE-side import permit because nothing is being imported into the UAE. The UAE-side documents that matter are the travel and immigration documents, the medical records package for the destination center, and the financial commitment paperwork.

Carvykti REMS, boxed warnings, and the monitoring window

Carvykti carries a boxed warning for cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), parkinsonism and Guillain-Barre syndrome, hemophagocytic lymphohistiocytosis or macrophage activation syndrome, and prolonged or recurrent cytopenia. Each of these can be fatal or life-threatening. The Carvykti REMS Program requires that the product be shipped only to REMS-certified treatment centers (typically NCI-designated cancer centers and qualifying academic medical centers) that have completed Carvykti REMS training in CRS and ICANS management. Patients are monitored at least daily for 10 days at the certified facility following infusion, are advised to remain within proximity of the treatment center for at least 4 weeks, and are restricted from driving or operating heavy machinery for at least 8 weeks given the risk of delayed neurotoxicity. Long-term follow-up for CAR-T cell therapies is generally 15 years per FDA guidance.

The parkinsonism boxed warning is specific to the BCMA CAR-T class and was a defining post-marketing finding from the CARTITUDE program. Patients receiving Carvykti are monitored for new-onset parkinsonian features (tremor, bradykinesia, rigidity, gait disturbance) and changes in mental status throughout the post-infusion window and beyond. This is one of the reasons a UAE patient cannot simply receive an infusion in a non-certified setting and then return home for monitoring. The 4-week proximity rule, the daily 10-day monitoring period, and the 8-week driving restriction shape the full travel-and-stay calendar.

The apheresis-manufacture-return cycle: the operational complexity vs typical NPP

For a routine named-patient case (an oral oncology tablet, a subcutaneous biologic), the medicine moves and the patient stays. For Carvykti, the patient and the medicine make a round trip. The cycle looks like this. Leukapheresis at the qualified collection site (typically 1 day on-site) draws the patient's T-cells. The collected cells move under cryogenic shipping to a Janssen-Legend manufacturing facility (Raritan, New Jersey for US-routed cases; Ghent, Belgium for European-routed cases). Manufacturing takes approximately 30 to 45 days from apheresis to product release, depending on manufacturing slot availability and batch release testing. During the manufacturing window, the treating hematologist often gives bridging therapy to control disease, and the patient may travel back to the UAE between apheresis and the return for lymphodepletion plus infusion, or may remain in the destination country depending on disease tempo and family logistics. Lymphodepleting chemotherapy (cyclophosphamide 300 mg per square meter intravenously plus fludarabine 30 mg per square meter intravenously daily for 3 days) starts 5 to 7 days before infusion. A single Carvykti intravenous infusion follows. Post-infusion monitoring at the REMS-certified facility runs at least daily for 10 days and the proximity-to-center expectation extends through week 4. Total operational arc, apheresis through end of immediate monitoring window, is approximately 6 to 10 weeks. There is no maintenance dose; Carvykti is a one-time infusion with the goal of durable remission.

For a UAE family, that arc means flights, accommodation, medical visas where required, school and work coordination, and a continuity-of-care plan with the home UAE hematologist for the post-week-4 phase. This is the part Reserve Meds carries on the patient side. We are not the prescriber, not the apheresis center, not the manufacturer, and not the infusion center. We are the coordinator that lets the family hold the cycle calendar in one place and lets the home UAE hematologist coordinate the handoff back.

Where Carvykti gets administered (not in the UAE)

UAE oncology centers (Sheikh Khalifa Medical City, Cleveland Clinic Abu Dhabi, Tawam Hospital, American Hospital Dubai, King's College Hospital London Dubai, Mediclinic City Hospital, the larger NMC Healthcare sites) handle multiple myeloma diagnostic workup, prior-line therapy management, bridging therapy during the Carvykti manufacturing wait, and post-week-4 follow-up. These centers do not infuse Carvykti themselves. The infusion happens at a manufacturer-certified treatment center in the US (a wide network of NCI-designated centers), the EU (centers qualifying under EMA risk-management frameworks), the UK (centers qualifying under MHRA frameworks), or Japan (centers qualifying under PMDA frameworks). Reserve Meds does not select the destination center; the treating UAE hematologist, in coordination with their international colleague at the destination, sets that choice based on slot availability, family geography, payment posture, and patient-specific factors.

Real cost picture for Carvykti for a UAE patient

The US wholesale acquisition cost for Carvykti is approximately USD 465,000 per single infusion per Janssen's launch pricing as reported by Fierce Pharma. That covers the manufactured CAR-T product only. The total per-patient cost of care is materially higher and typically includes leukapheresis, bridging therapy, lymphodepleting chemotherapy, the infusion, an inpatient or close-observation hospitalization window of 1 to 2 weeks, outpatient monitoring through week 4, and management of any CRS, ICANS, parkinsonian features, or other complications. Real-world all-in costs reported in US commercial and Medicare settings range from approximately USD 600,000 to over USD 1,000,000 per patient depending on complications and length of stay.

At the UAE dirham peg of approximately 3.67 AED to 1 USD, the drug-only figure translates to roughly AED 1.71 million, and the all-in cost envelope for a UAE patient traveling for the full episode lands at AED 2.2 to 3.7 million for the medical course alone, before accommodation, travel for family, and ancillary expenses. EMA-region negotiated pricing at the national-health-system level is lower per the molecule but is generally not accessible to a cash-pay UAE-resident patient outside the destination country's payer system. For a UAE patient who is a US or EU resident-equivalent through insurance carriers operating across borders, additional pathways may exist; Reserve Meds confirms the patient-specific picture rather than republishing list prices as if they apply uniformly. International logistics in the conventional Reserve Meds sense (US-to-UAE shipment) does not apply to Carvykti because the product does not travel to the UAE. Travel logistics for the patient and family does apply, and that is itemized separately on every firm quote.

Typical timeline for a Carvykti-pursuing UAE patient

Indicative timeline (not a promise). Week 0 to 2: Reserve Meds confirms eligibility, the treating UAE hematologist completes the medical records package, and the destination Carvykti REMS-certified center conducts intake review and confirms apheresis eligibility. Week 2 to 4: travel logistics finalize (visas, flights, accommodation), the patient arrives at the destination center, apheresis is performed. Week 4 to 9: manufacturing window of 30 to 45 days from apheresis to release. Bridging therapy may run at the destination center or back in the UAE under the treating hematologist's care. Week 9 to 10: lymphodepleting chemotherapy over 3 days, infusion, immediate post-infusion monitoring at the certified facility. Week 10 to 14: continued monitoring at the destination center under the daily-for-10-days and stay-within-proximity-for-4-weeks rules. Week 14 onward: return to the UAE for ongoing follow-up under the treating UAE hematologist, with the destination center retained for the 15-year long-term CAR-T follow-up cadence. Manufacturing slot availability is the constraint that most often shifts this arc; Q4 2025 Carvykti sales of approximately USD 555 million per Legend's preliminary release reflect expanded throughput at Raritan and Ghent, but slot wait times remain a real factor in patient sequencing decisions.

What your physician needs to provide

The UAE-side documentation set is a medical records package for the destination center, not an EDE import permit. The treating hematologist supplies: confirmed multiple myeloma diagnosis with cytogenetics and risk stratification, prior-line therapy history with response and duration for each line, lenalidomide-refractory status documentation if pursuing under the second-line label, current performance status (ECOG), organ function (cardiac echocardiogram, pulmonary function tests, liver function, renal function), absence of active central nervous system involvement and active autoimmune disease, prior bridging therapy plan, and the destination center coordination contacts. The destination Carvykti REMS-certified center conducts its own apheresis eligibility review under its standard intake process. Reserve Meds does not substitute for that review and does not weigh in on the choice between Carvykti and Abecma; that decision sits with the treating hematologist in consultation with the destination center.

Common questions about Carvykti for UAE patients

Can Carvykti be infused in the UAE?
Not currently. There is no Carvykti REMS-certified treatment center in the UAE as of this review. The infusion happens at a qualified center in the US, EU, UK, or Japan, and the patient travels for the apheresis and infusion phases.

Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, or Orient cover travel-for-treatment Carvykti?
Each insurer assesses this case by case, and most UAE plans do not extend to overseas CAR-T at this price tier without specific cross-border provisions. Thiqa, the government-funded programme for UAE nationals administered by Daman, has more latitude for medically necessary cross-border treatment than commercial plans. Cash-pay or family-financed is the typical posture; we supply documentation that lets the insurer or government program assess.

How long will my family be away from home?
Indicative range 10 to 14 weeks from apheresis through end of the 4-week proximity window, with shorter or longer arcs depending on manufacturing slot timing, complications, and follow-up cadence at the destination center.

What is the safety profile?
Carvykti carries a boxed warning for CRS, ICANS, parkinsonism and Guillain-Barre syndrome, hemophagocytic lymphohistiocytosis or macrophage activation syndrome, and prolonged or recurrent cytopenia. Each can be fatal or life-threatening. Hypogammaglobulinemia and serious infections are also common. Second primary malignancies, including T-cell malignancies, have been reported in the BCMA CAR-T class and are part of post-marketing surveillance. This is one of the reasons treatment must occur at a REMS-certified center with the monitoring infrastructure to manage these complications in real time.

Why Carvykti versus Abecma?
Both are BCMA CAR-T therapies. The CARTITUDE trials (Carvykti) and KarMMa trials (Abecma) are separate programs with different patient populations and follow-up durations. Treatment selection turns on prior lines, manufacturing slot availability, treatment center experience, and the treating hematologist's clinical judgment. Reserve Meds does not weigh in on this decision.

What happens for the 15-year follow-up?
The destination Carvykti center retains a long-term follow-up registry per FDA guidance for CAR-T cell therapies. The treating UAE hematologist coordinates the local follow-up with the destination center's registry, typically through annual data sharing.

Where Reserve Meds fits in Carvykti cases

Reserve Meds has no prior case experience on Carvykti at the date of this page, and we are direct that this is an exceptional rather than routine NPP case. Carvykti coordination value for a UAE family sits at the upstream and downstream edges of the destination center's process. Upstream, we help the family understand the apheresis-manufacture-return cycle, the 30 to 45 day manufacturing window, the 6 to 10 week operational arc, the cost envelope including hospitalization and complication management, and the boxed warnings. We help the treating UAE hematologist's medical records package arrive at the destination center cleanly. We coordinate travel, accommodation, and family logistics around the apheresis trip and the lymphodepletion-plus-infusion trip. Downstream, we coordinate the handoff back to the UAE hematologist for post-week-4 follow-up and the long-term CAR-T registry cadence. Reserve Meds does not administer Carvykti, does not infuse Carvykti, and does not make clinical decisions for cell therapy patients. We are a coordinator and a navigator, not a clinician.

Next step

Add your case to the Reserve Meds Carvykti-in-UAE waitlist. We confirm eligibility within 24 to 48 hours and route the medical records package to a destination Carvykti REMS-certified center in coordination with your treating UAE hematologist.

Reserved for you.

---

This guide is informational, not medical or legal advice. CAR-T cell therapy requires a licensed hematologist's clinical judgment and a manufacturer-certified treatment center; Reserve Meds is the coordinator, not the prescriber or infuser. Sources cited: FDA Carvykti approval letter (February 2022) and expanded approval (April 2024); FDA Approval Summary, Clinical Cancer Research 2024; CARTITUDE-4 efficacy reference; UAE country module 2026-05-11; Fierce Pharma Carvykti pricing reference.